2.58
+0.06(+2.38%)
Currency In USD
| Previous Close | 2.52 |
| Open | 2.55 |
| Day High | 2.66 |
| Day Low | 2.48 |
| 52-Week High | 36 |
| 52-Week Low | 2.33 |
| Volume | 71,411 |
| Average Volume | 209,368 |
| Market Cap | 6.99M |
| PE | -0.1 |
| EPS | -24.88 |
| Moving Average 50 Days | 2.62 |
| Moving Average 200 Days | 9.34 |
| Change | 0.06 |
If you invested $1000 in AIM ImmunoTech Inc. (AIM) 10 years ago, it would be worth $30.54 as of October 14, 2025 at a share price of $2.58. Whereas If you bought $1000 worth of AIM ImmunoTech Inc. (AIM) shares 5 years ago, it would be worth $1,053.06 as of October 14, 2025 at a share price of $2.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
GlobeNewswire Inc.
Sep 25, 2025 12:45 PM GMT
Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical market globally, with oncology as the fastest-grow
AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth
GlobeNewswire Inc.
Sep 22, 2025 1:00 PM GMT
New peer-reviewed article appears in the Journal for ImmunoTherapy of CancerOCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Journal for ImmunoTherapy of Canc
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
GlobeNewswire Inc.
Sep 04, 2025 3:00 PM GMT
AIM CEO Thomas K. Equels AIM CEO Thomas K. Equels Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSC